The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Learn how nonalcoholic fatty liver disease develops, its warning signs, and the steps to help safeguard the liver.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Squibb announced that the U.S. Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for adult ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma ...

Investigators conducted a systematic review and meta-analysis of more than 100 studies primarily from Asia, Europe, and the US to evaluate hepatocellular carcinoma outcomes on the basis of age.

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.